Details
Stereochemistry | RACEMIC |
Molecular Formula | C20H24N2 |
Molecular Weight | 292.418 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C1=C(CCN(C)C)CC2=C1C=CC=C2)C3=CC=CC=N3
InChI
InChIKey=MVMQESMQSYOVGV-UHFFFAOYSA-N
InChI=1S/C20H24N2/c1-15(19-10-6-7-12-21-19)20-17(11-13-22(2)3)14-16-8-4-5-9-18(16)20/h4-10,12,15H,11,13-14H2,1-3H3
Molecular Formula | C20H24N2 |
Molecular Weight | 292.418 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: https://www.drugbank.ca/drugs/DB08801
Sources: https://www.drugbank.ca/drugs/DB08801
Dimetindene (trade name Fenistil; other name dimethindene maleate) is a potent antipruritic antihistamine, characterized by the small size of its effective dose and its rapidity of action. Dimetindene is an antihistamine/anticholinergic that is a selective H1 antagonist. Its effect sets in after 20 to 60 minutes and lasts several hours. Dimetindene drops as well as Dimetindene syrup is particularly indicated in pediatric practice. Dimetindene is indicated as symptomatic treatment of allergic reactions: urticaria, allergies of the upper respiratory tract such as hay fever and perennial rhinitis, food, and drug allergies; pruritus of various origins, except pruritus due to cholestasis; insect bites. Dimetindene is also indicated for pruritus in eruptive skin diseases such as chicken-pox. Dimetindene can be as an adjuvant in eczema and other pruriginous dermatoses of allergic origin.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12593665 |
0.692 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: http://pcm.me/fenistil-%C2%AE/ |
Primary | Fenistil Approved UseUnknown |
||
Sources: http://pcm.me/fenistil-%C2%AE/ |
Primary | Fenistil Approved UseUnknown |
||
Sources: http://pcm.me/fenistil-%C2%AE/ |
Primary | Fenistil Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
14.6 ng/mL |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIMETHINDENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
101.3 ng × h/mL |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIMETHINDENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5.41 h |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIMETHINDENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
0.28 mg 2 times / day multiple, intranasal Recommended Dose: 0.28 mg, 2 times / day Route: intranasal Route: multiple Dose: 0.28 mg, 2 times / day Sources: |
unhealthy, 18 -69 n = 76 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 18 -69 Sex: M+F Population Size: 76 Sources: |
|
0.1 % 1 times / day single, topical Highest studied dose Dose: 0.1 %, 1 times / day Route: topical Route: single Dose: 0.1 %, 1 times / day Sources: |
healthy, 33 (21-54) n = 24 Health Status: healthy Age Group: 33 (21-54) Sex: M+F Population Size: 24 Sources: |
|
6 mg 1 times / day single, oral Highest studied dose Dose: 6 mg, 1 times / day Route: oral Route: single Dose: 6 mg, 1 times / day Sources: |
healthy, adult n = 60 Health Status: healthy Age Group: adult Sex: M Population Size: 60 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
[Systemic mastocytosis. Classification, symptoms, therapy]. | 2004 Mar 15 |
|
[Separation of dimetinden enantiomers in drugs by means of capillary isotachophoresis]. | 2006 Jan |
|
Comparison of capillary zone electrophoresis and isotachophoresis determination of dimethindene enantiomers in pharmaceuticals using charged carboxyethyl-beta-cyclodextrin as a chiral selector. | 2006 Nov |
|
Characterization of antihistamine-human serum protein interactions by capillary electrophoresis. | 2007 Apr 20 |
|
Determination of dimethindene enantiomers in pharmaceuticals by capillary electrophoresis with carboxyethyl-beta-cyclodextrin. | 2007 Jan |
|
Antagonist affinity measurements at the Gi-coupled human histamine H3 receptor expressed in CHO cells. | 2008 Jun 6 |
|
Application of HILIC stationary phase to determination of dimethindene maleate in topical gel. | 2009 Aug 15 |
|
Garlic-induced severe anaphylaxis in a nonatopic patient. | 2010 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://pcm.me/fenistil-%C2%AE/
Drops: Infants up to 1 year, 10-30 drops; Infants of 1 to 3 years, 30-45 drops; Children over 3 years, 45-60 drops; Adults, 60-120 drops.
Syrup: Infants up to 1 year, 1-3 teaspoons; Infants of 1 to 3 years, 3-4 teaspoons; Children over 3 years, 4-6 teaspoons; Adults, 6-12 teaspoons. 1 teasponful Fenistil syrup = 5ml = 0.5mg
Coated tablets: Adults, 3-6 tablets.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6832322
Experiments were carried out on isolated right ventricular papillary muscle of cat and guinea-pig, and on left atrial muscle of guinea-pig. The animals were anesthetized
with ether, and the muscles were dissected from the heart as quickly as possible and mounted in an organ chamber. The preparations were driven electrically at 2.0 or 0.5 Hz. The transmembrane potentials were recorded by means of conventional glass microelectrode technique. The slow response APs were elicited with histamine (10^-5 M) ) or caffeine (2 mM) in partially depolarized (up to -40 mV) left atrial and right ventricular.myocardium of guinea-pigs. The membrane was depolarized by means of elevated K + (26 mM)-Krebs solution. Dimetindene was freshly dissolved and added to the organ chamber containing Krebs solution (composition in mM): NaC1 118, KCl 4.7, CaC12 2.5, NaH2PO4 1.0, MgC12 1.2, NaHCO3 24.9, glucose 11.5, which was gassed with 95% 02 and 5% CO2 and kept at 37C
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:11:24 GMT 2023
by
admin
on
Fri Dec 15 15:11:24 GMT 2023
|
Record UNII |
661FH77Z3P
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
D04AA13
Created by
admin on Fri Dec 15 15:11:24 GMT 2023 , Edited by admin on Fri Dec 15 15:11:24 GMT 2023
|
||
|
WHO-ATC |
R06AB03
Created by
admin on Fri Dec 15 15:11:24 GMT 2023 , Edited by admin on Fri Dec 15 15:11:24 GMT 2023
|
||
|
WHO-VATC |
QD04AA13
Created by
admin on Fri Dec 15 15:11:24 GMT 2023 , Edited by admin on Fri Dec 15 15:11:24 GMT 2023
|
||
|
WHO-VATC |
QR06AB03
Created by
admin on Fri Dec 15 15:11:24 GMT 2023 , Edited by admin on Fri Dec 15 15:11:24 GMT 2023
|
||
|
NCI_THESAURUS |
C29578
Created by
admin on Fri Dec 15 15:11:24 GMT 2023 , Edited by admin on Fri Dec 15 15:11:24 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
903
Created by
admin on Fri Dec 15 15:11:24 GMT 2023 , Edited by admin on Fri Dec 15 15:11:24 GMT 2023
|
PRIMARY | |||
|
D004115
Created by
admin on Fri Dec 15 15:11:24 GMT 2023 , Edited by admin on Fri Dec 15 15:11:24 GMT 2023
|
PRIMARY | |||
|
C83675
Created by
admin on Fri Dec 15 15:11:24 GMT 2023 , Edited by admin on Fri Dec 15 15:11:24 GMT 2023
|
PRIMARY | |||
|
Dimetindene
Created by
admin on Fri Dec 15 15:11:24 GMT 2023 , Edited by admin on Fri Dec 15 15:11:24 GMT 2023
|
PRIMARY | |||
|
21855
Created by
admin on Fri Dec 15 15:11:24 GMT 2023 , Edited by admin on Fri Dec 15 15:11:24 GMT 2023
|
PRIMARY | |||
|
5636-83-9
Created by
admin on Fri Dec 15 15:11:24 GMT 2023 , Edited by admin on Fri Dec 15 15:11:24 GMT 2023
|
PRIMARY | |||
|
SUB07179MIG
Created by
admin on Fri Dec 15 15:11:24 GMT 2023 , Edited by admin on Fri Dec 15 15:11:24 GMT 2023
|
PRIMARY | |||
|
m4508
Created by
admin on Fri Dec 15 15:11:24 GMT 2023 , Edited by admin on Fri Dec 15 15:11:24 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000082645
Created by
admin on Fri Dec 15 15:11:24 GMT 2023 , Edited by admin on Fri Dec 15 15:11:24 GMT 2023
|
PRIMARY | |||
|
661FH77Z3P
Created by
admin on Fri Dec 15 15:11:24 GMT 2023 , Edited by admin on Fri Dec 15 15:11:24 GMT 2023
|
PRIMARY | |||
|
661FH77Z3P
Created by
admin on Fri Dec 15 15:11:24 GMT 2023 , Edited by admin on Fri Dec 15 15:11:24 GMT 2023
|
PRIMARY | |||
|
1403
Created by
admin on Fri Dec 15 15:11:24 GMT 2023 , Edited by admin on Fri Dec 15 15:11:24 GMT 2023
|
PRIMARY | |||
|
DB08801
Created by
admin on Fri Dec 15 15:11:24 GMT 2023 , Edited by admin on Fri Dec 15 15:11:24 GMT 2023
|
PRIMARY | |||
|
DTXSID9022942
Created by
admin on Fri Dec 15 15:11:24 GMT 2023 , Edited by admin on Fri Dec 15 15:11:24 GMT 2023
|
PRIMARY | |||
|
CHEMBL22108
Created by
admin on Fri Dec 15 15:11:24 GMT 2023 , Edited by admin on Fri Dec 15 15:11:24 GMT 2023
|
PRIMARY | |||
|
3449
Created by
admin on Fri Dec 15 15:11:24 GMT 2023 , Edited by admin on Fri Dec 15 15:11:24 GMT 2023
|
PRIMARY | RxNorm | ||
|
227-083-8
Created by
admin on Fri Dec 15 15:11:24 GMT 2023 , Edited by admin on Fri Dec 15 15:11:24 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT | |||
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |